OncoXchange welcomes you to participate in the CPD-accredited program Neoadjuvant Versus Adjuvant Approaches in Early TNBC, presented by Javier Cortés, MD, PhD. Based on a session presentation from ESMO 2019, Dr. Cortés reviews the goals of neoadjuvant therapy in breast cancer; explains the basis for pathologic complete response (pCR) as a surrogate endpoint for long-term outcomes in triple-negative breast cancer (TNBC); and summarizes the key biology-driven clinical trial data with application in both neoadjuvant and adjuvant settings. In addition, Dr. Cortés discusses an emerging framework for medical treatment strategies in clinical stages I and II TNBC, where neoadjuvant therapy is integrated with post-surgical treatment options in both pCR and residual disease settings.
